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 The majority of rectal cancer patients are elderly. Biological age, not chronological age alone, is the main risk factor of 
postoperative morbidity in this group. Therefore, based on the Comprehensive Geriatric Assessment, we can differentiate 
three groups of patients: fit, pre-frail and frail. In the fit group, a standard multimodal oncologic treatment can be offered. 
In the pre-frail group, prerehabilitation should be recommended to improved resilience to surgical stress. In frail patients, 
a tailored approach should be discussed in a geriatric multidisciplinary team meeting. At present, a whole range of multi-
modal tailored approaches can be offered to rectal cancer patients. In this group, of much more importance is postoperative 
functional recovery, including both organ-specific outcomes and the ability to regain independence than currently used 
outcome indicators. Therefore, as important as cancer staging and tumour biology, it is crucial to understand the health 
status of an older patient with rectal cancer.
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The majority of rectal cancer (RC) patients are elderly, dia-
gnosed at a median age of 70 years. However, the risk of 
developing rectal cancer still increases with age, so octo- 
and nonagenarians with rectal tumours are, currently, also 
not a rarity [1]. 
The major problem in tailored treatment of RC in older 
patients is still the lack of good research data. Older patients 
are still not sufficiently included in studies. In 2019, Abbasi et al. 
demonstrated that the proportion of older patients in clinical 
trials is <25% (age 65–74 years) and <10% (age 75 and more), 
respectively [2]. In turn, Schiphorst et al., analysing the partici-
pation of older patients in laparoscopic surgery for colorectal 
cancer, showed that the median age was less than 65 years 
in 86% of the studies, and 44% of the studies excluding the 
elderly [3]. This shows that the guidelines for the treatment 
of the elderly are still based on the extrapolation of evidence 
obtained from studies including patients from younger age 
groups or older patients who were completely healthy. The-
refore, older patients with RC are often under-treated due to 
their chronological age or poorly evaluated co-morbidities, 
or over-treated due to failures in recognising the frailty status 
of the patient [4]. 
Due to improvements in anaesthesia, surgical techniques 
and perioperative care in developed countries, significant 
decreases in perioperative morbidity and mortality are ob-
servable. However, the 5-year absolute survival and disease-
-free survival of older patients are still significantly poorer in 
comparison to younger patients. Therefore, increasing the 
awareness of physicians treating RC is one of the main goals 
of this mini-review based on recently published studies and 
the expert recommendations  of the European Society of Sur-
gical Oncology, the European Society of Coloproctology, the 
International Society of Geriatric Oncology, and the American 
College of Surgeons Commission on Cancer [5–9]. 
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Preoperative assessment and treatment 
decisions
As was mentioned in our previous publications, the population 
of older patients is very heterogeneous in terms of co-mor-
bidity, physical reserve, cognitive function and social support 
[10, 11]. Current routine preoperative assessment also cannot 
adequately identify patients at risk. Therefore, the compre-
hensive geriatric assessment (CGA) was introduced to help 
determine the primary status of the older patient, to diagnose 
frailty syndrome (surrogate of biological age) and to identify 
how to optimise the patient’s condition before the start of the 
treatment. A standardised preoperative diagnostic approach, 
individualised surgical technique selection and tailored po-
stoperative care are essential for the successful treatment of 
older patients [6, 12]. In general, based on the CGA, we can 
differentiate 3 groups of older patients: 
1.  Fit: patients without any deficits in the CGA domains and 
less than 80 years old. In this group, the standard oncologic 
treatment can be offered and the postoperative outcomes 
are comparable with younger patients.
2.  Pre-frail: patients with 1 or 2 deficits in the CGA domains 
or more than 80 years old. In these patients, pre-rehabili-
tation should be recommended to improve resilience to 
surgical stress by, at least, augmenting functional capacity 
and nutritional status before surgery.
3.  Frail: patients with 3 or more impaired domains in the 
CGA or 80 years old with 2 deficits in the CGA. A tailored 
approach should be discussed in a geriatric multidiscipli-
nary team meeting [6].
Important treatment outcomes for older patients
The outcomes of cancer treatment in older patients should be 
evaluated differently and should be discussed with the patient 
before surgery. The 5-year overall survival, the disease specific 
survival, or the progression-free survival are well established 
indicators to define cancer control. However, these indicators 
have limited value for patients aged 80+ years, and particularly, 
for frail patients independent of their chronological age. In this 
group, of much more importance is the functional recovery 
indicators, including both organ-specific postoperative outco-
mes and the ability to regain independence. In the case of rec-
tal cancer, organ-specific’ outcomes should include evaluation 
of urinary, sexual, bowel function, faecal incontinence and, in 
the case of a diverting loop ileostomy, its closure after primary 
operation. Similarly, we need more studies on the time and 
level of posttreatment independence restoration. Good quality 
data on these topics in frail patients are still not available [5].
Treatment of rectal cancer in older patients
Table I presents the therapeutic options for rectal cancer pa-
tients depending on the risk group based on guidelines, sup-
plemented by information on possible treatment options for 
frail patients [7]. However, it must be stressed that diagnosing 
frailty in a patient is not a contraindication for surgery. It is a sign 
that standard oncologic treatment can lead to unacceptable 
results; major morbidity, permanent disability, institutionalisa-
tion and death. Moreover, frailty is not a qualitative indicator 
(present or not). It can be quantified and there are significant 
differences between mild and severely frail patients.
Table I. Therapeutic options for rectal cancer patients depending on the risk group [7], including options for frail older patients
Risk group Stage factors Fit patients Frail patients 
very early cT1 sm1–2, N0 local excision 
TME in case of sm3, IMVI(+), 
G3–4
• local excision 
early cT1–2
cT3aN0, middle or high rectum,  
MRF(–), EMVI(–)
CT3aN1 high rectum, MRF(–), EMVI(–)
TME
in case of CRM(+), N2: adjuvant 
treatment
• local excision +/– adjuvant treatment
• prerehabilitation followed by TME
• neoadjuvant CRTh with watch-and-wait strategy in 
case of complete clinical response 
• palliative care in sever frailty
intermediate cT3a/b in low rectum, levators    
clear, MRF(–)
cT3a/b in mid- or high rectum,
cN1–2, no EMVI
neoadjuvant RTh (5 x 5 Gy) or 
CRTH followed by TME
• neoadjuvant rth 5 x 5 with longer time interval (in the 
mean time prerehabilitation) and TME 
• neoadjuvant CRTh with watch-and-wait strategy in 
case of complete clinical response (in the mean time 
prerehabilitation)
• prerehabilitation followed by TME
• palliative care in sever frailty
advanced cT3 with MRF(+)
any cT4a–b
pelvic lateral N+ 
neoadjuvant CRTh followed by 
TME or more extended surgery  
• neoadjuvant RTh 5 x 5 with longer time interval (in 
the mean time prerehabilitation) and TME or more 
extended surgery 
• neoadjuvant CRTh (in the mean time prerehabilitation) 
followed by TME or more extended surgery  
• palliative care in sever frailty
sm – submucosa; V1 – cancer cells in the vessels; G – grading; CRM – circumferential resection margin; MRF – mesorectal fascia; EMVI – presence of extramural venous invasion; 
IMVI – intramural vascular invasion; TME – total mesorectal excision; RTh – radiotherapy; CRTh – chemoradiotherapy
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Local excision (irrespective of platform used), in experience 
hands, can achieve good oncologic results, sparing the rectum, 
while lowering morbidity (7–14%) with very good functional 
results (1% urinary dysfunction, <1 faecal incontinence) [5]. 
According to the guidelines, the rectal cancer most suitable for 
local excision is T1 cancer with submucosal invasion <1000 µm, 
without lymphovascular invasion, well-differentiated and with 
budding grade 1. There are several studies on its use in T1 
rectal cancer with poor pathology and T2 tumours with/wi-
thout neodjuvant/adjuvant treatment or its combination. This 
strategy cannot be regarded as a standard of treatment due 
to the high recurrence rate. However, it can be considered in 
frail patients in combination with or without neo-/adjuvant 
treatment. Studies clearly show that neoadjuvant treatment 
is connected to a higher complication rate in comparison to 
adjuvant treatment. [13, 14].
There is still the belief that older patients cannot undergo 
a total mesorectal excision (TME) due to the high rate of pe-
rioperative complications. In the past, this type of operation 
was not advised in patients aged 75 years or more [15]. As was 
mentioned before, currently the chronological age alone does 
not determine the choice of treatment. 
Similarly, advanced age had initially been viewed as a re-
lative contraindication to minimal invasive surgery due to the 
physiologic influence of pneumoperitoneum on the older 
patient. Based on well-known trials, COLOR II, CLASICC, COST, 
we know that minimal invasive rectal cancer surgery is safe and 
has comparable oncological results as open surgery [16–18]. 
None of these studies excluded elderly patients based on their 
chronological age. However, older patients were underrepre-
sented compared to younger patients. Li Y et al. analysed 11 
studies on colorectal resection in octogenarians and proved 
that laparoscopy is safe and carries a lower risk of infectious 
complications (pulmonary and surgical site), a shorter length 
of hospital stay and a reduced incidence of postoperative ileus 
while maintaining the same cardiovascular risk as compared 
to open surgery [19]. These benefits are pointed out by Se-
nagore et al., showing decreased direct costs associated with 
laparoscopic surgery in older patients [20]. A study of 33,000 
patients in the Netherland’s Cancer Registry showed that the 
reduction in 1-year mortality associated with laparoscopic 
resection was greatest in the population of patients greater 
than 75 years of age [21]. However, laparoscopic TME is still 
performed in only 10–50% of all rectal cancers with a high 
conversion rate (up to 30%).  
A few published studies on robotic colorectal surgery in 
the geriatric population reported similar oncologic outcomes 
to the laparoscopic approach, although with increased costs 
and longer operative time [22–24].
Studies on Transanal TME (taTME) in older patients are 
not currently available. Based on data from the International 
taTME registry, managed by the Pelican Cancer Foundation, 
in 92% of the older study population, a sphincter-preserving 
procedure was carried out. The conversion rate was low (5%). 
The overall 30-day mortality and morbidity were 1% and 38%, 
respectively. There was no difference in the number of surgical 
complications between the older and younger rectal cancer 
patients. Therefore, age alone is not a contraindication to mi-
nimal invasive surgery. Laparoscopy seems to be the preferred 
option to perform TME surgery in older patients. The benefits 
of laparoscopy are consistent with the expectations of geriatric 
surgery [5].
Neoadjuvant chemoradiation
Neoadjuvant radiotherapy is the standard treatment for locally-
-advanced mid-distal rectal cancer to increase local control. If 
the radial margin is not threatened, the preoperative radio-
therapy 5 x 5 Gy with immediate operation is most commonly 
used. In frail patients, a longer time (4–8 weeks) between 
the end of the radiation and the surgery is recommended to 
reduce the complication rate. Over this time, prerehabiliation 
can be carried out to improve resilience to surgical stress by, 
at least, augmenting functional capacity and nutritional status 
before surgery. In the case of a larger tumour, with a threate-
ned radial margin, a 45–50 Gy dose of radiotherapy is given 
over 5 weeks. Concurrent chemotherapy is also administered. 
However, in older patients, the toxicity of this treatment may 
compromise the chance of TME surgery, which is the main 
treatment for local control and curative intent. In turn, in up 
to 25–30%, a complete clinical response can be achieved [25]. 
This so-called watch and wait strategy, allows to preserve 
rectum avoids preoperative morbidity, a permanent stoma or 
long-term functional problems associated with TME surgery. 
However, up to 30% have a regrowth. Detected early, it can be 
successfully treated with delayed TME surgery.
Smith et al. compared cohorts: 60-year-old men with mild 
co-morbidities, 80-year-olds with minor co-morbidities, and 
80-year-olds with significant co-morbidities. Patients with 
a complete clinical response after chemoradiotherapy were 
followed according to the watch and wait protocol or had 
TME. There was no difference in absolute survival in 60-year-old 
patients from the watch and wait and TME group. However, 
in both the 80-year-old groups, there was a 10.1% survival 
advantage at the one year mark in those who underwent 
a watch and wait protocol [26, 27]. 
Adjuvant chemotherapy
Adjuvant chemotherapy is typically given following surgical 
resection with or without neoadjuvant chemoradiotherapy. 
Several studies have been carried out to evaluate the benefits 
of adjuvant chemotherapy for rectal cancer. Breugom et al. 
and Bujko et al. performed two meta-analyses on this topic. 
The first showed no difference in overall survival, disease free 
survival, or the rate of distant recurrence. In a subgroup analysis, 
the authors observed an increase in disease free survival and 
a decreased rate of distant recurrences in tumours between 
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10 and 15 cm from the anal verge [28]. The second showed no 
benefit for postoperative chemotherapy in improving overall 
survival or disease free survival [29]. Therefore, the SIOG con-
sensus on postoperative chemotherapy in colorectal cancer 
in older patients advocates a risk-balanced approach [30]. 
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